Search
4 articles for “BRAF”
-
Melanogenic Inhibitory Effects of Sesamum indicum Phytocompounds Towards CDK 2, c-KIT, and BRAF.
Abstract: Objective: Melanoma is thought to be the fifth most frequent cancer in the US population, despite cancer being the most common cause of death in the globe. BRAF, CDK2, and c-KIT proteins are regarded as potential therapeutic agents since mutations in these proteins are the primary cause of melanoma. For the investigation of their pharmacological properties and therapeutic activities against the target proteins, Sesamum indicum L. and its phytocompounds were …
Published in International Journal of Bioinformatics and Computational Biology Read article
-
Mass Spectrometry–Based Phosphoproteomic Markers to Predict Kinase Inhibitor Response in Solid Tumors
Abstract: Mass spectrometry-based phosphoproteomics has emerged as a powerful tool for predicting kinase inhibitor responses in solid tumors, offering direct functional insights into signaling pathways that surpass traditional genomic profiling by capturing dynamic kinase activities and adaptive resistance mechanisms. Technological breakthroughs, including data- independent acquisition (DIA), trapped ion mobility spectrometry (timsTOF), and efficient enrichment methods like TiO2 or IMAC, now enable comprehensive profiling of over 40,000 phosphorylation sites from limited clinical …
Published in International Journal of Cell Biology and Cellular Functions · Vol. 4, Issue 2, 2026 Read article
-
Efficacy of Combination Therapy with Osimertinib and Afatinib in epidermal growth factor receptor-mutant non-small-cell lung cancer Patients
Abstract: Treatment options for patients with non-small-cell lung cancer who have epidermal growth factor receptor mutations are constrained by the emergence of resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Osimertinib or afatinib alone, when tested in a laboratory model, led to the formation of drug-resistant clones harboring epidermal growth factor receptor secondary mutations. However, combining these drugs prevented the emergence of such mutations. In a Phase II clinical trial, …
Published in Research and Reviews: Journal of Oncology and Hematology · Vol. 13, Issue 1, 2024 · pp. 13–24 Read article
-
Mystic Malignant Melanoma Modalities
Abstract: Melanoma is a highly aggressive form of cancer with four recognized subtypes. In about 90% of cases, melanoma is diagnosed as a primary tumor, without signs of spreading. If caught early, the survival rate is quite high, reaching around 94%. However, for metastatic melanoma, the survival rate drops significantly to about 40%. Diagnosing melanoma can be tricky, as it shares features with benign conditions like seborrheic keratosis, benign moles, blue …
Published in Research and Reviews: Journal of Oncology and Hematology · Vol. 13, Issue 3, 2024 · pp. 1–10 Read article